Moxetumomab pasudotox
An immunotoxin for hairy cell leukaemia that produced lasting remissions in relapsed patients but was withdrawn from sale in 2023 for commercial reasons.
Pivotal study (Kreitman, Leukemia 2018): 41% complete remission (30% durable) in multiply relapsed HCL. Capillary leak and haemolytic uraemic syndrome were the key toxicities. AstraZeneca withdrew it from the US market in 2023 (low use); a compassionate supply continued via the NIH.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2018 | Relapsed/refractory hairy cell leukaemia after ≥2 systemic therapies including a purine analogue — Withdrawn from market 2023 |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Moxetumomab pasudotox" OR ABSTRACT:"Moxetumomab pasudotox" OR TITLE:"Lumoxiti" OR ABSTRACT:"Lumoxiti") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Moxetumomab pasudotox, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetCD73 / adenosine axis
Shares AstraZeneca and the tag gap-fill.
- ProductPivekimab sunirine
Shares Antibody-drug conjugate (ADC) and the tag gap-fill.
- TargetCD79b
Shares Antibody-drug conjugate (ADC) and the tag gap-fill.
- TargetClaudin 6
Shares Antibody-drug conjugate (ADC) and the tag gap-fill.
- TargetPRMT5 (MTAP-deleted cancers)
Shares AstraZeneca and the tag gap-fill.
- TargetMUC16 (CA-125)
Shares Antibody-drug conjugate (ADC) and the tag gap-fill.
- ProductCladribine
Shares Hairy cell leukaemia and the tag gap-fill.
- ProductInterferon alfa-2a/2b
Shares Hairy cell leukaemia and the tag gap-fill.